Angiotensin 1-7 promotes cardiac angiogenesis following infarction

Current Vascular Pharmacology

Volumn 13, Issue 1, 2015, Pages 37-42

  Zhao, Wenyuan ^a   Zhao, Tieqiang ^a   Chen, Yuanjian ^a   Sun, Yao ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Ang(1 7); Angiogenesis; Cardiac repair; Mas receptor blockade; Myocardial infarction; Ventricular dysfunction

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN [1-7] [7 DEXTRO ALANINE]; ANGIOTENSIN[1-7]; BETA3 INTEGRIN; CD31 ANTIGEN; G PROTEIN COUPLED RECEPTOR; GELATINASE B; MAS RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN D; ANGIOTENSIN I; ANGIOTENSIN I (1-7); DIPEPTIDYL CARBOXYPEPTIDASE; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTO-ONCOGENE PROTEINS C-MAS-1;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING; ANIMAL; HEART MUSCLE; HEART VENTRICLE REMODELING; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANGIOTENSIN I; ANIMALS; FEMALE; MATRIX METALLOPROTEINASE 9; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VENTRICULAR REMODELING;

EID: 84930917391     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990006     Document Type: Article

References (47)

1. [1] Sun Y, Diaz-Arias AA, Weber KT. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res 1994; 28: 1423-32.
2. [2] Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995; 27(6): 1281-92.
3. [3] Nelson MA, Passeri J, Frishman WH. Therapeutic angiogenesis: a new treatment modality for ischemic heart disease. Heart Dis 2000; 2(4): 314-25.
4. [4] Zhao W, Zhao T, Chen Y, Ahokas RA, Sun Y. Reactive oxygen species promote angiogenesis in the infarcted rat heart. Int J Exp Pathol 2009; 90(6): 621-9.
5. [5] Yang F, Yang XP, Liu YH, et al. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 2004; 43(2): 229-36.
6. [6] Qin D, Zhang ZH, Caref EB, Boutjdir M, Jain P, el-Sherif N. Cellular and ionic basis of arrhythmias in postinfarction remodeled ventricular myocardium. Circ Res 1996; 79(3): 461-73.
7. [7] Sun Y, Zhang J, Zhang JQ, Weber KT. Renin expression at sites of repair in the infarcted rat heart. J Mol Cell Cardiol 2001; 33: 995-1003.
8. [8] Passier RC, Smits JF, Verluyten MJ, Daemen MJ. Expression and localization of renin and angiotensinogen in rat heart after myocardial infarction. Am J Physiol 1996; 271: H1040-8.
9. [9] Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodeling in myocardial-infarcted rats. J Mol Cell Cardiol 1993; 25: 1369-80.
10. [10] Falkenhahn M, Gohlke P, Paul M, Stoll M, Unger T. The reninangiotensin system in the heart and vascular wall: new therapeutic aspects. J Cardiovasc Pharmacol 1994; 24(Suppl 2): S6-13
11. [11] Dzau VJ. Local expression and pathophysiological role of reninangiotensin in the blood vessels and heart. Basic Res Cardiol 1993; 88(Suppl 1): 1-14.
12. [12] Raizada V, Skipper B, Luo W, Griffith J. Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects. J Investig Med 2007; 55: 341-59.
13. [13] Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 2003; 13: 93-101.
14. [14] Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 2004; 15: 166-9.
15. [15] Der Sarkissian S, Grobe JL, Yuan L, et al. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 2008; 51: 712-8.
16. [16] Wysocki J, Ye M, Rodriguez E, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 2010; 55: 90-8.
17. [17] Kassiri Z, Zhong J, Guo D, et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2009; 2: 446-55.
18. [18] Mercure C, Yogi A, Callera GE, et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 2008; 103: 1319-26.
19. [19] Yamamoto K, Ohishi M, Katsuya T, et al. Deletion of angiotensinconverting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006; 47: 718-26.
20. [20] Qi Y, Shenoy V, Wong F, et al. Lentivirus-mediated overexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology. Exp Physiol 2011; 96(9): 863-74.
21. [21] Ferreira AJ, Shenoy V, Qi Y, et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 2011; 96(3): 287-94.
22. [22] Zhong J, Basu R, Guo D, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010; 122(7): 717-28.
23. [23] Mercure C, Yogi A, Callera GE, et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 2008; 103(11): 1319-26.
24. [24] Marques FD, Melo MB, Souza LE, et al. Beneficial effects of longterm administration of an oral formulation of Angiotensin-(1-7) in infarcted rats. Int J Hypertens 2012; 2012: 795452.
25. [25] Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407: 249–257.
26. [26] Goede V, Brogelli L, Ziche M, Augustin HG. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 1999; 82(5): 765-70.
27. [27] Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005; 9(2): 267-85.
28. [28] Pandya NM, Dhalla NS, Santani DD. Angiogenesis--a new target for future therapy. Vascul Pharmacol 2006; 44(5): 265-74.
29. [29] Boodhwani M, Sodha NR, Laham RJ, Sellke FW. The future of therapeutic myocardial angiogenesis. Shock 2006; 26(4): 332-41.
30. [30] Rodgers KE, Espinoza T, Felix J, Roda N, Maldonado S, di Zerega G. Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7). Plast Reconstr Surg 2003; 111(3): 1195-206.
31. [31] Günay GK, Ozyazgan I, Soyuer I. The effect of angiotensin (1-7) on survival of random pattern skin flaps with nicotine-induced ischemia in rats. Ann Plast Surg 2012; 68(1): 88-93.
32. [32] Lovren F, Pan Y, Quan A, et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol 2008; 295(4): H1377-84.
33. [33] van Hinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 2008; 78(2): 203-12.
34. [34] Am_linei C, C_runtu ID, B_lan RA. Biology of metalloproteinases. Rom J Morphol Embryol 2007; 48(4): 323-34.
35. [35] Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005; 1755(1): 37-69.
36. [36] Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253(1-2): 269-85
37. [37] Lambert E, Dassé E, Haye B, Petitfrère E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49(3): 187-98.
38. [38] Tessone A, Feinberg MS, Barbash IM, et al. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction. Cardiovasc Drugs Ther 2005; 19(6): 383-90.
39. [39] Samolov B, Steen B, Seregard S, van der Ploeg I, Montan P, Kvanta A. Delayed inflammation associated corneal neovascularization in MMP-2-deficient mice. Exp Eye Res 2005; 80(2): 159-66.
40. [40] Jadhav U, Chigurupati S, Lakka SS, Mohanam S. Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int J Oncol 2004; 25(5): 1407-14.
41. [41] Rupp PA, Little CD. Integrins in vascular development. Circ Res 2001; 89: 566–572.
42. [42] Giancotti, FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-1032.
43. [43] Sun M, Opavsky MA, Stewart DJ, et al. Temporal response and localization of integrins beta1 and beta3 in the heart after myocardial infarction: regulation by cytokines. Circulation 2003; 107(7): 1046-52.
44. [44] Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13(1): 9-22.
45. [45] Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996; 270(5 Pt 2): H1803-11.
46. [46] Zhao T, Zhao W, Chen Y, Ahokas RA, Sun Y. Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction. Microvasc Res 2010; 80(2): 188-94.
47. [47] Zhao T, Zhao W, Chen Y, Liu L, Ahokas RA, Sun Y. Differential expression of vascular endothelial growth factor isoforms and receptor subtypes in the infarcted heart. Int J Cardiol 2013; 167(6): 2638-45